Hemoglobin crosfumaril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hemoglobin crosfumaril
Accession Number
DB13864
Type
Biotech
Groups
Experimental
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Hemoglobin in which the alpha-subunit are cross-linked intramolecularly.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • DCLHb
  • Hemoglobin A0 (human alpha2 beta2 tetrameric subunit), alpha-chain 99,99'-diamide with (E)-2-butenoic acid
International/Other Brands
HemAssist
Categories
UNII
FXP28WJO7L
CAS number
142261-03-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Hemoglobin crosfumaril.Approved
AcarboseHemoglobin crosfumaril may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolHemoglobin crosfumaril may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hemoglobin crosfumaril.Approved, Vet Approved
AlbiglutideHemoglobin crosfumaril may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Aldosterone.Experimental, Investigational
AlogliptinHemoglobin crosfumaril may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Hemoglobin crosfumaril.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved
Ammonium chlorideThe serum concentration of Hemoglobin crosfumaril can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Hemoglobin crosfumaril.Approved
AncrodHemoglobin crosfumaril may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Hemoglobin crosfumaril.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Anistreplase.Approved
Antithrombin III humanHemoglobin crosfumaril may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanHemoglobin crosfumaril may increase the anticoagulant activities of Apixaban.Approved
ArdeparinHemoglobin crosfumaril may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Hemoglobin crosfumaril.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hemoglobin crosfumaril.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Hemoglobin crosfumaril.Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Batroxobin.Experimental
BecaplerminHemoglobin crosfumaril may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Hemoglobin crosfumaril.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Betamethasone.Approved, Vet Approved
BivalirudinHemoglobin crosfumaril may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Brinzolamide.Approved
BromocriptineHemoglobin crosfumaril may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Hemoglobin crosfumaril.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Hemoglobin crosfumaril.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Hemoglobin crosfumaril.Investigational
CanagliflozinHemoglobin crosfumaril may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Hemoglobin crosfumaril.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Caplacizumab.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental, Investigational
CertoparinHemoglobin crosfumaril may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamideHemoglobin crosfumaril may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Hemoglobin crosfumaril.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Hemoglobin crosfumaril.Approved, Investigational
Citric AcidHemoglobin crosfumaril may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Hemoglobin crosfumaril.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Hemoglobin crosfumaril.Experimental
ClorindioneHemoglobin crosfumaril may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Cortisone acetate.Approved, Investigational
Dabigatran etexilateHemoglobin crosfumaril may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinHemoglobin crosfumaril may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidHemoglobin crosfumaril may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinHemoglobin crosfumaril may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanHemoglobin crosfumaril may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Hemoglobin crosfumaril.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
DersalazineDersalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Investigational
DesirudinHemoglobin crosfumaril may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Dexketoprofen.Approved, Investigational
DextranHemoglobin crosfumaril may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Diclofenamide.Approved, Investigational
DicoumarolHemoglobin crosfumaril may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved, Investigational
DiphenadioneHemoglobin crosfumaril may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hemoglobin crosfumaril.Approved
DisopyramideHemoglobin crosfumaril may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideHemoglobin crosfumaril may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
Edetic AcidHemoglobin crosfumaril may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanHemoglobin crosfumaril may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinHemoglobin crosfumaril may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Hemoglobin crosfumaril.Approved
EnoxaparinHemoglobin crosfumaril may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Hemoglobin crosfumaril.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Hemoglobin crosfumaril.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Hemoglobin crosfumaril.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Hemoglobin crosfumaril.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Hemoglobin crosfumaril.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateHemoglobin crosfumaril may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideHemoglobin crosfumaril may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Ferulic acidHemoglobin crosfumaril may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fludrocortisone.Approved, Investigational
FluindioneHemoglobin crosfumaril may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Flurandrenolide.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone propionate.Approved
FondaparinuxHemoglobin crosfumaril may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumHemoglobin crosfumaril may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Vet Approved
GabexateHemoglobin crosfumaril may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved, Investigational, Nutraceutical
GliclazideHemoglobin crosfumaril may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideHemoglobin crosfumaril may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideHemoglobin crosfumaril may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideHemoglobin crosfumaril may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with HE3286.Investigational
HeparinHemoglobin crosfumaril may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Hemoglobin crosfumaril.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Hemoglobin crosfumaril.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Hemoglobin crosfumaril.Approved, Investigational, Nutraceutical
IdraparinuxHemoglobin crosfumaril may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Hemoglobin crosfumaril.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Hemoglobin crosfumaril.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Hemoglobin crosfumaril.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Hemoglobin crosfumaril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Hemoglobin crosfumaril.Investigational
Insulin AspartHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Hemoglobin crosfumaril.Investigational
LepirudinHemoglobin crosfumaril may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanHemoglobin crosfumaril may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Hemoglobin crosfumaril.Experimental
LiraglutideHemoglobin crosfumaril may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with ME-609.Investigational
MecaserminHemoglobin crosfumaril may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Medrysone.Approved
MelagatranHemoglobin crosfumaril may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved
MetforminHemoglobin crosfumaril may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Hemoglobin crosfumaril.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hemoglobin crosfumaril.Approved
Methyl salicylateHemoglobin crosfumaril may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Methylprednisolone.Approved, Vet Approved
MifepristoneHemoglobin crosfumaril may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolHemoglobin crosfumaril may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Hemoglobin crosfumaril.Approved
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Mometasone.Approved, Vet Approved
NadroparinHemoglobin crosfumaril may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatHemoglobin crosfumaril may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Hemoglobin crosfumaril.Investigational
NateglinideHemoglobin crosfumaril may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Hemoglobin crosfumaril.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hemoglobin crosfumaril.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Hemoglobin crosfumaril.Investigational
OtamixabanHemoglobin crosfumaril may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateHemoglobin crosfumaril may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineHemoglobin crosfumaril may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateHemoglobin crosfumaril may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Hemoglobin crosfumaril.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
PhenindioneHemoglobin crosfumaril may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonHemoglobin crosfumaril may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Hemoglobin crosfumaril.Experimental
PioglitazoneHemoglobin crosfumaril may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Hemoglobin crosfumaril.Approved
Potassium CitrateHemoglobin crosfumaril may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Hemoglobin crosfumaril.Approved, Investigational
PramlintideHemoglobin crosfumaril may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Hemoglobin crosfumaril.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
Protein CHemoglobin crosfumaril may increase the anticoagulant activities of Protein C.Approved
Protein S humanHemoglobin crosfumaril may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeHemoglobin crosfumaril may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Hemoglobin crosfumaril.Approved
QuinineHemoglobin crosfumaril may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Hemoglobin crosfumaril.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Hemoglobin crosfumaril.Investigational
RepaglinideHemoglobin crosfumaril may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Hemoglobin crosfumaril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hemoglobin crosfumaril.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Reteplase.Approved, Investigational
ReviparinHemoglobin crosfumaril may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Hemoglobin crosfumaril.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Rimexolone.Approved
RivaroxabanHemoglobin crosfumaril may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Rosiglitazone.Approved, Investigational
Salicylic acidSalicylic acid may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved, Investigational, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Hemoglobin crosfumaril.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Saruplase.Experimental
SaxagliptinHemoglobin crosfumaril may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hemoglobin crosfumaril.Approved, Vet Approved
SitagliptinHemoglobin crosfumaril may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateHemoglobin crosfumaril may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Hemoglobin crosfumaril.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Streptokinase.Approved, Investigational
SulfadiazineHemoglobin crosfumaril may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleHemoglobin crosfumaril may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleHemoglobin crosfumaril may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulodexideHemoglobin crosfumaril may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibHemoglobin crosfumaril may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Hemoglobin crosfumaril.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Hemoglobin crosfumaril.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Tinzaparin.Approved
TioclomarolHemoglobin crosfumaril may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Hemoglobin crosfumaril.Approved
TixocortolThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Tixocortol.Approved, Withdrawn
TolazamideHemoglobin crosfumaril may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideHemoglobin crosfumaril may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Hemoglobin crosfumaril.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Hemoglobin crosfumaril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Hemoglobin crosfumaril.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Hemoglobin crosfumaril.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Hemoglobin crosfumaril.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Hemoglobin crosfumaril.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Hemoglobin crosfumaril.Approved, Investigational
Trolamine salicylateHemoglobin crosfumaril may increase the anticoagulant activities of Trolamine salicylate.Approved
TroxerutinHemoglobin crosfumaril may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Hemoglobin crosfumaril.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Hemoglobin crosfumaril.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Hemoglobin crosfumaril.Approved
WarfarinHemoglobin crosfumaril may increase the anticoagulant activities of Warfarin.Approved
XimelagatranHemoglobin crosfumaril may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
B05AA08 — Hemoglobin crosfumaril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 26, 2017 14:27 / Updated on June 02, 2018 08:56